Lincoln Pharmaceuticals Ltd Q3FY21 consolidated PAT drops QoQ to Rs. 13.48 crore

LINCOLN PHARMACEUTICALS LTD. has reported financial results for the period ended December 31, 2020.

Financial Results (Q3 FY20-21) - QoQ Comparison

The company has reported total income of Rs.115.47 crores during the period ended December 31, 2020 as compared to Rs.126.66 crores during the period ended September 30, 2020.

The company has posted net profit / (loss) of Rs.13.48 crores for the period ended December 31, 2020 as against net profit / (loss) of Rs.20.91 crores for the period ended September 30, 2020.

The company has reported EPS of Rs.6.74 for the period ended December 31, 2020 as compared to Rs.10.46 for the period ended September 30, 2020.

Financials	Q3 FY20-21	Q2 FY20-21	% Change
Total Income	₹ 115.47 crs	₹ 126.66 crs	-8.83%
Net Profit	₹ 13.48 crs	₹ 20.91 crs	-35.53%
EPS	₹ 6.74	₹ 10.46	-35.56%

Financial Results (Q3 FY20-21) - YoY Comparison

The company has reported total income of Rs.115.47 crores during the period ended December 31, 2020 as compared to Rs.101.55 crores during the period ended December 31, 2019.

The company has posted net profit / (loss) of Rs.13.48 crores for the period ended December 31, 2020 as against net profit / (loss) of Rs.10.91 crores for the period ended December 31, 2019.

The company has reported EPS of Rs.6.74 for the period ended December 31, 2020 as compared to Rs.5.46 for the period ended December 31, 2019.

Financials	Q3 FY20-21	Q3 FY19-20	% Change
Total Income	₹ 115.47 crs	₹ 101.55 crs	13.71%
Net Profit	₹ 13.48 crs	₹ 10.91 crs	23.56%
EPS	₹ 6.74	₹ 5.46	23.44%

Financial Results (9 Months ended FY 20-21) - YoY Comparison

The company has reported total income of Rs.347.73 crores during the 9 months period ended December 31, 2020 as compared to Rs.314.87 crores during the 9 months period ended December 31, 2019.

The company has posted net profit / (loss) of Rs.49.65 crores for the 9 months period ended December 31, 2020 as against net profit / (loss) of Rs.42.49 crores for the 9 months period ended December 31, 2019.

The company has reported EPS of Rs.24.83 for the 9 months period ended December 31, 2020 as compared to Rs.21.25 for the 9 months period ended December 31, 2019.

Financials	9 Months ended FY20-21	9 Months ended FY19-20	% Change
Total Income	₹ 347.73 crs	₹ 314.87 crs	10.44%
Net Profit	₹ 49.65 crs	₹ 42.49 crs	16.85%
EPS	₹ 24.83	₹21.25	16.85%

Commenting on the results and performance/ Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, "On back of strong domestic and international business, company posted 15.56 % sales growth, 4.00 % rise in exports and 31.35 % rise in the PAT for the quarter ended Q3FY21. Exports sales in nine months ended December 2020 was reported at Rs. 212.47 crore, growth of 17.56 % Y-o-Y. Geographical and product expansion coupled with operational efficiency contributing to the growth. Company is in the process of expanding presence in Africa, South East Asian countries and exploring entry in EU. Expanding the product basket, company will be introducing 6-7 new products in the domestic markets and expects 20-25 new dossiers approval for the exports market."

Shares of LINCOLN PHARMACEUTICALS LTD. was last trading in BSE at Rs.232 as compared to the previous close of Rs. 222.95. The total number of shares traded during the day was 18658 in over 737 trades.

The stock hit an intraday high of Rs. 237.8 and intraday low of 220.9. The net turnover during the day was Rs. 4324353.

Source : Equity Bulls

Keywords